Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Nephrology

The Diagnostic Path: Genetic Testing and Biopsy

At a Glance

Genetic testing is now the gold standard for diagnosing Alport syndrome, providing a definitive answer by identifying COL4A mutations without surgery. A kidney biopsy may still be used if genetic results are unclear or to assess current kidney damage using advanced microscopy.

Getting an accurate diagnosis is the most important step in managing Alport syndrome. Historically, this required an invasive kidney biopsy. Today, however, the diagnostic pathway has shifted significantly toward genetic testing as the first and most definitive step [1][2][3].

Why Genetic Testing First?

Genetic testing is now considered the “gold standard” because it provides a clear, definitive answer without the need for surgery [4][2]. Unlike a biopsy, which looks at the damage already done, a genetic test identifies the root cause by looking at the COL4A3, COL4A4, and COL4A5 genes [1][5].

The Genetic Report Checklist

A complete genetic report should include specific details to help your doctor predict your prognosis:

  • The Gene Involved: Identifies if it is XLAS (COL4A5), ARAS, or ADAS (COL4A3/4) [1].
  • Mutation Type: Specifies if it is truncating (a major “stop” signal) or missense (a “typo”), which helps predict the age of kidney failure [6][7].
  • Inheritance Pattern: Explains how the gene was passed down (e.g., X-linked, recessive, or dominant) [8].
  • Zygosity: Notes if there is one mutation (heterozygous) or two (homozygous or compound heterozygous), which is critical for understanding severity [9][10].

When a Kidney Biopsy is Used

While genetic testing is preferred, your doctor might still recommend a kidney biopsy if the genetic results are unclear or if they need to see the current level of kidney damage [11][12].

What the Pathologist Looks For

A biopsy report for Alport syndrome typically focuses on two advanced techniques:

  1. Electron Microscopy (EM): This uses a powerful microscope to see the Glomerular Basement Membrane (GBM). In Alport syndrome, the GBM often appears uneven, with areas that are too thin and areas that are thickened and “split.” This characteristic “basket-weave” appearance is a classic sign of the disease [7][13].
  2. Immunofluorescence (IF): The pathologist uses special glowing “tags” to see if the alpha-3, alpha-4, and alpha-5 collagen chains are present. In many cases of Alport syndrome, these chains will be missing or patchy [14][15].

Differentiating Alport from TBMN

A concept that frequently causes confusion is the relationship between Alport syndrome and Thin Basement Membrane Nephropathy (TBMN).

Historically, TBMN was thought of as a completely separate, benign condition where patients had a thin GBM but rarely progressed to kidney failure. Today, the medical consensus has shifted: nephrologists increasingly recognize TBMN as a milder presentation on the Alport “collagen spectrum,” often reclassifying it under Autosomal Dominant Alport Syndrome (ADAS) [16][17].

Because both conditions are linked to the same genes, it is critical to understand that even a “TBMN” or milder ADAS presentation requires lifelong monitoring, as some patients can develop increasing proteinuria and kidney decline over time [1][18]. Genetic testing is often the most reliable way to map out this spectrum and ensure appropriate care [19][20].

Common questions in this guide

Why is genetic testing the first step in diagnosing Alport syndrome?
Genetic testing is now the gold standard because it is non-invasive and provides a definitive answer. It identifies the specific mutations in the COL4A3, COL4A4, or COL4A5 genes that cause the disease without needing surgery.
Will I still need a kidney biopsy if I have a genetic test?
You may still need a kidney biopsy if your genetic test results are unclear. Your nephrologist might also order one to see the current extent of damage to your kidneys and evaluate the glomerular basement membrane.
What does a kidney biopsy show for Alport syndrome?
A biopsy uses electron microscopy to look at the kidney's filtration barrier, known as the Glomerular Basement Membrane. In Alport syndrome, this membrane typically has a characteristic 'basket-weave' appearance with alternating thick and thin areas.
What is the difference between Alport syndrome and Thin Basement Membrane Nephropathy (TBMN)?
TBMN was once considered a separate, benign condition but is now understood to be a milder presentation on the Alport syndrome spectrum. Because they share the same genetic causes, people with TBMN still require lifelong kidney monitoring.
What do 'truncating' and 'missense' mean on an Alport genetic test report?
A truncating mutation acts like a major 'stop' signal in the gene, usually leading to earlier and more severe kidney issues. A missense mutation is more like a 'typo' and often results in a later onset of severe kidney problems.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why did you choose genetic testing over a biopsy (or vice versa) in my case?
  2. 2.Does my genetic report clearly identify which gene is affected and whether the mutation is 'truncating' or 'missense'?
  3. 3.If we have a biopsy report, what does the electron microscopy say about the thickness and structure of the GBM?
  4. 4.Does my pathology report show staining for the alpha-3, alpha-4, and alpha-5 chains? What were the results?
  5. 5.Based on these tests, how certain are we of the specific subtype and inheritance pattern?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Comparison between conventional and comprehensive sequencing approaches for genetic diagnosis of Alport syndrome.

    Yamamura T, Nozu K, Minamikawa S, et al.

    Molecular genetics & genomic medicine 2019; (7(9)):e883 doi:10.1002/mgg3.883.

    PMID: 31364286
  2. 2

    Next-Generation Sequencing-Based Genetic Diagnostic Strategies of Inherited Kidney Diseases.

    Zhang J, Zhang C, Gao E, Zhou Q

    Kidney diseases (Basel, Switzerland) 2021; (7(6)):425-437 doi:10.1159/000519095.

    PMID: 34901190
  3. 3

    [Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023)].

    , ,

    Zhonghua yi xue za zhi 2023; (103(20)):1507-1525 doi:10.3760/cma.j.cn112137-20230203-00161.

    PMID: 37246000
  4. 4

    Alport syndrome with bilateral simultaneous anterior and posterior lenticonus with severe temporal macular thinning.

    Gupta V, Jamil M, Luthra S, Puthalath AS

    BMJ case reports 2019; (12(8)) doi:10.1136/bcr-2019-229554.

    PMID: 31420426
  5. 5

    Phenotype-genotype correlations in patients with Alport syndrome from the Polish population.

    Malarska M, Moczulska H, Pachniak P, et al.

    Journal of nephrology 2025; (38(7)):1831-1839 doi:10.1007/s40620-025-02251-3.

    PMID: 40237890
  6. 6

    A Systematic Review of Pathogenic COL4A5 Variants and Proteinuria in Women and Girls With X-linked Alport Syndrome.

    Gibson JT, de Gooyer M, Huang M, Savige J

    Kidney international reports 2022; (7(11)):2454-2461 doi:10.1016/j.ekir.2022.08.021.

    PMID: 36531881
  7. 7

    Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome.

    Akihisa T, Sato M, Wakayama Y, et al.

    Kidney medicine 2019; (1(6)):391-396 doi:10.1016/j.xkme.2019.06.007.

    PMID: 32734219
  8. 8

    Clinical, histological and molecular characteristics of Alport syndrome in Chinese children.

    Zhou L, Xi B, Xu Y, et al.

    Journal of nephrology 2023; (36(5)):1415-1423 doi:10.1007/s40620-023-01570-7.

    PMID: 37097554
  9. 9

    A Deeper Insight into COL4A3, COL4A4, and COL4A5 Variants and Genotype-Phenotype Correlation of a Turkish Cohort with Alport Syndrome.

    Yavas C, Ozgenturk NO, Dogan M, et al.

    Molecular syndromology 2024; (15(1)):1-13 doi:10.1159/000533915.

    PMID: 38357258
  10. 10

    The heterozygous mutation COL4A4 c.817-1G>A causes Alport syndrome in a Chinese family: a case report.

    Wang D, Li X, Cheng K, et al.

    Frontiers in pediatrics 2025; (13()):1533638 doi:10.3389/fped.2025.1533638.

    PMID: 40406358
  11. 11

    Genetic diagnosis and renal biopsy findings in the setting of a renal genetics clinic.

    Ben Moshe Y, Bekheirnia N, Smith RJH, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2022; (190(3)):302-308 doi:10.1002/ajmg.c.32009.

    PMID: 36239278
  12. 12

    A child with familial glomerulonephritis: Answers.

    Pennesi M, Squillaci D, Diomedi-Camassei F, et al.

    Pediatric nephrology (Berlin, Germany) 2020; (35(10)):1873-1875 doi:10.1007/s00467-020-04551-1.

    PMID: 32291534
  13. 13

    Slowly Progressive Male Alport Syndrome Evaluated by Serial Biopsy: Importance of Type IV Collagen Staining.

    Sato M, Manabe S, Itabashi M, et al.

    Internal medicine (Tokyo, Japan) 2022; (61(8)):1205-1209 doi:10.2169/internalmedicine.7372-21.

    PMID: 34645753
  14. 14

    Macroscopic hematuria with normal renal biopsy-following the chain to the diagnosis: Answers.

    Truong J, Deschênes G, Callard P, et al.

    Pediatric nephrology (Berlin, Germany) 2017; (32(2)):279-281 doi:10.1007/s00467-015-3268-2.

    PMID: 26628280
  15. 15

    A family case of X-linked Alport syndrome patients with a novel variant in COL4A5.

    Kashiwagi Y, Suzuki S, Agata K, et al.

    CEN case reports 2019; (8(2)):75-78 doi:10.1007/s13730-018-0368-4.

    PMID: 30293132
  16. 16

    Family Genetic Screening to Identify Cases of Alport Syndrome: A Case Study Report.

    Sprague SM, Warady BA

    Kidney medicine 2021; (3(5)):866-867 doi:10.1016/j.xkme.2021.05.005.

    PMID: 34693267
  17. 17

    Familial hematuria: A review.

    Plevová P, Gut J, Janda J

    Medicina (Kaunas, Lithuania) 2017; (53(1)):1-10 doi:10.1016/j.medici.2017.01.002.

    PMID: 28236514
  18. 18

    A novel variant in the COL4A3 gene: etiology of Alport syndrome type 2 in a 38-year-old male with suspected hereditary kidney disease.

    Sienes Bailo P, Bancalero Flores JL, Lahoz Alonso R, et al.

    Advances in laboratory medicine 2021; (2(3)):451-462 doi:10.1515/almed-2021-0058.

    PMID: 37362409
  19. 19

    Guidelines for Genetic Testing and Management of Alport Syndrome.

    Savige J, Lipska-Zietkiewicz BS, Watson E, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2022; (17(1)):143-154 doi:10.2215/CJN.04230321.

    PMID: 34930753
  20. 20

    Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.

    Kashtan CE, Gross O

    Pediatric nephrology (Berlin, Germany) 2021; (36(3)):711-719 doi:10.1007/s00467-020-04819-6.

    PMID: 33159213

This page explains diagnostic tests for Alport syndrome for educational purposes only. Always consult a nephrologist or genetic counselor to interpret your specific genetic and biopsy results.

Get notified when new evidence is published on Alport syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.